Nanobiotix (0QAV – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on the stock and has a €10.00 price target.
Swayampakula Ramakanth has given his Buy rating due to a combination of factors that highlight Nanobiotix’s promising future prospects. The company is poised for a data-rich 2025, with significant clinical updates expected from multiple ongoing studies. These include the Phase 1 Study 1100 evaluating NBTXR3 in combination with anti-PD-1 therapy for various cancers, and a detailed analysis of NBTXR3’s potential in treating pancreatic ductal adenocarcinoma, a condition with limited treatment options.
Furthermore, Nanobiotix is advancing its Curadigm platform, which could enhance drug bioavailability and open up collaborative and licensing opportunities. The potential for milestone payments from Janssen Pharmaceuticals, contingent on positive study outcomes, could significantly bolster Nanobiotix’s financial position. These payments, if realized, would provide non-dilutive funding, extending the company’s financial runway and supporting its strategic initiatives.
In another report released yesterday, Stifel Nicolaus also maintained a Buy rating on the stock with a €16.00 price target.